[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-alcoholic-fatty-liver\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-alcoholic-fatty-liver":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,40,97,120,144,166],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100053683","high-intensity-interval-training-versus-moderate-intensity-continuous-training-on-gut-microbiota-in-non-alcoholic-fatty-liver-100053683",false,"NCT07697313","High-intensity Interval Training Versus Moderate Intensity Continuous Training on Gut Microbiota in Non-alcoholic Fatty Liver","Inclusion Criteria:\n\n1. Patients from both genders aged 40 - 60 years old diagnosed with Non-alcoholic Fatty Liver disease by ultrasonography.\n2. Body mass index will range from 30 to 34.9 kg\u002Fm².\n3. Patients with central obesity (waist circumference 90 cm for men and 85 cm for women).\n4. Patients who have taken no regular exercise in the last year (\\\u003C3 times\u002Fweek and 30 min\u002Ftime.\n5. No antibiotic or probiotic use for at least last 3 months.\n6. Medical drugs such as metformin, sulfonylureas, statins, and blood pressure medication were eligible, as well as stable.\n\nExclusion Criteria:\n\n1. History of liver cirrhosis or other chronic liver diseases.\n2. Use of medications affecting gut microbiota (e.g., laxatives, metformin, proton pump inhibitors).\n3. Recent gastrointestinal infections or surgeries.\n4. Diabetes Mellitus type 1 or uncontrolled type 2.\n5. Cardiovascular, respiratory, or musculoskeletal disorders limiting exercise capacity.\n6. Active smokers.\n7. Pregnancy or breastfeeding.\n8. Uncontrolled hypertension.\n9. Communication disorders.\n10. Bleeding disorders.","ALL","40 Years","60 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","To compare High-Intensity Interval Training versus moderate intensity continuous training on gut microbiota in Non- Alcoholic Fatty Liver.",[26],"Non-alcoholic Fatty Liver","NOT_YET_RECRUITING","2026-07-05",{"date":30,"type":31},"2026-07-13","ACTUAL",{"date":33,"type":20},"2026-07-10",{"date":35,"type":20},"2026-10-10",{"name":37,"class":38},"Horus University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":51,"conditions":52,"keywords":72,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100526751","effect-of-endoscopic-sleeve-gastroplasty-in-patients-with-obesity-and-mash-a-randomized-controlled-trial-100526751","NCT06138821","Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial","Effect of Endoscopic Sleeve Gastroplasty on Patients With Obesity and Concomitant Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Multicenter, Open-label, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18 (male or female)\n2. BMI ≥30 kg\u002Fm2 or ≥27 kg\u002Fm2 with at least one obesity-related comorbidity\n3. Self-reported stable weight (no weight change \\>5%) for 6 months prior to the first study visit\n4. Willingness to follow protocol requirements, including signed informed consent, routine follow-up schedule, completing laboratory\u002Fimaging\u002Fadditional tests, and completing diet counseling\n5. Willingness to NOT start a new anti-obesity medication for the following 12 months\n6. Residing within a reasonable distance from the investigator's office and able to travel to the investigator to complete routine follow-up visits\n7. Ability to give informed consent\n8. Women of childbearing potential (i.e., not post-menopausal, nor surgically sterilized) must agree to use adequate birth control methods\n\nExclusion Criteria:\n\n1. Known history of other chronic liver diseases (viral hepatitis, autoimmune hepatitis, drug-induced hepatitis, and genetic)\n2. Treatment with vitamin E (at doses ≥800 IU\u002Fday), pioglitazone, obeticholic acid, or resmetirom \\\u003C90 days before the first study visit\n3. History of foregut or gastrointestinal (GI) surgery (except uncomplicated fundoplication, cholecystectomy or appendectomy)\n4. Prior bariatric surgery\n5. Prior endoscopic sleeve gastroplasty\n6. Any inflammatory disease of the GI tract, including severe (LA Grade C or D) esophagitis, Barrett's esophagus with dysplasia, gastric ulceration, duodenal ulceration, cancer or specific inflammation such as Crohn's disease\n7. Potential upper gastrointestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasis, or other congenital anomalies of the gastrointestinal tract such as atresias or stenoses\n8. Severe gastroesophageal reflux disease (GERD)\n9. A structural abnormality in the esophagus or pharynx, such as a stricture or diverticulum, that could impede passage of the endoscope.\n10. Achalasia or any other severe esophageal motility disorder\n11. Chronic abdominal pain\n12. Gastroparesis or intractable constipation\n13. Hepatic insufficiency or cirrhosis\n14. Severe coagulopathy\n15. Insulin-dependent diabetes (either type 1 or type 2) or a significant likelihood of requiring insulin treatment in the following 12 months or HgbA1C ≥ 12%\n16. Patients on an anti-platelet agent, anticoagulant agent or chronic\u002Froutine use of NSAIDs\n17. Patients on corticosteroids, immunosuppressants, or narcotics\n18. Patients on an anti-seizure or anti-arrhythmic medication\n19. Patients who are pregnant or breastfeeding\n20. Excessive alcohol consumption (\\>20 g per day for women; \\>30 g per day for men)\n21. Active smoking\n22. History of poorly controlled hypertension, coronary artery disease, congestive heart failure, cardiac arrhythmia\n23. History of respiratory diseases such as chronic obstructive pulmonary disease (COPD) requiring steroids, pneumonia, or cancer\n24. History of autoimmune connective tissue disorder such as lupus, scleroderma or immunocompromised disease\n25. History of active malignancy\n26. History of genetic or hormonal causes for obesity, such as Prader Willi syndrome\n27. History of endocrine disorders affecting weight, such as uncontrolled hypothyroidism\n28. Eating disorders, including night eating syndrome, bulimia, binge eating disorder or compulsive overeating\n29. Active psychological issues preventing participation in a lifestyle modification program as determined by a psychologist","18 Years",{"count":49,"type":20},132,[23],"Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the standard treatment, most patients regain weight limiting ultimate improvement in liver disease. On the other end of the spectrum, bariatric surgery has shown promise in the treatment of MASLD\u002Fmetabolic dysfunction-associated steatohepatitis (MASH) due to its efficacy in inducing weight loss. Nevertheless, its adoption has been hindered by the perceived invasiveness of surgery.\n\nOver the past decade, endoscopic sleeve gastroplasty (ESG) has gained recognition as a promising minimally-invasive approach to weight loss. The procedure involves utilizing a Food and Drug Administration (FDA)-authorized endoscopic suturing device to reduce the gastric volume by 70%. Studies reveal that ESG is associated with approximately 18.2% weight loss at one year after the procedure, with sustained results for at least 10 years. Nevertheless, the effect of ESG on MASH remains unknown.\n\nIn this study, the investigators will compare ESG + lifestyle modification versus lifestyle modification alone in treating histologic MASH. The study will randomize patients to one of two different treatment options: ESG + lifestyle modification or lifestyle modification alone.",[53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71],"Obesity","Liver Diseases","Liver Fibrosis","Liver Fat","Metabolic Dysfunction-Associated Steatotic Liver Disease","Metabolic Dysfunction-Associated Steatohepatitis","MASLD","MASH","Weight Loss","Insulin Resistance","Insulin Sensitivity","Insulin Sensitivity\u002FResistance","Metabolic Disease","Diabetes","Diabetes Mellitus, Type 2","NASH With Fibrosis","Non-Alcoholic Fatty Liver Disease","Non Alcoholic Fatty Liver","Non-alcoholic Steatohepatitis",[73,74,75,76,77,78,79,80,81,82,83,84,85],"Gut Hormones","Endoscopic Bariatric and Metabolic Therapy (EBMT)","Intragastric Balloon (IGB)","Endoscopic Suturing","Endoscopic Sleeve Gastroplasty (ESG)","Weight Management","Endoscopic Gastric Remodeling (EGR)","Endoscopic Bariatric Therapy (EBT)","Fatty Liver","Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","Metabolic Dysfunction-Associated Steatohepatitis (MASH)","Non-Alcoholic Fatty Liver Disease (NAFLD)","Non-Alcoholic Steatohepatitis (NASH)","RECRUITING","2026-06-23",{"date":89,"type":31},"2026-06-25",{"date":91,"type":31},"2025-06-24",{"date":93,"type":20},"2028-06",{"name":95,"class":38},"Pichamol Jirapinyo, MD, MPH",2,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":15,"minAge":47,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":96},"100579101","identification-of-liver-fibrosis-biomarkers-100579101","NCT06819917","Identification of Liver Fibrosis Biomarkers","Prospective Sample Collection Study for Discovery and Evaluation of Novel Blood Based Biomarkers for Assessment of Hepatic Fibrosis","Inclusion Criteria:\n\n* Patients scheduled for biopsy (or F0-F2 patients that underwent biopsy within the last 6 months but at least 1 month ago) suspected of having hepatic fibrosis due to NAFLD (NAFL\u002FNASH) or patients with MASLD or MASH\n* Any FIB-4 value available\n* Any Fibroscan value available\n* Written and signed informed consent present\n* Patients aged ≥ 18 years to ≤ 75 years at the time of the blood draw\n* Body Mass Index (BMI) ≤ 45 kg\u002Fm²\n\nExclusion Criteria:\n\n* Vulnerable person: person deprived of liberty by a judicial or administrative decision and\u002For person under psychiatric care\n* Self-reported pregnancy or lactating females\n* Disease related to other etiologies, including alcoholic liver disease (alcoholic steatohepatitis), MetALD, specific etiology SLD (e.g. DILI or monogenic disease), cryptogenic SLD, viral hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, human immunodeficiency virus, Wilson's disease, Hemochromatosis, alpha-1 antitrypsin deficiency\n* Any type of carcinoma, unless it is at least 5 years in remission\n* Prior liver transplant\n* Evidence of any other unstable or, untreated clinically significant immunological, neoplastic, endocrine, haematological, gastrointestinal, neurological or psychiatric disorder. Medically controlled comorbidities can be allowed\n* Self-reported alcohol consumption greater 30 g\u002Fday (males) 20 g\u002Fday (females)\n* Recent myocardial infarction (within last 6 months)\n* Inability to have a liver biopsy, or provide blood sample in a fasted status\n* F0-F2 recalled patients with +\u002F- 5% change in weight between the biopsy and study inclusion","75 Years",{"count":106,"type":20},575,"OBSERVATIONAL","Chronic liver disease (CLD) is a major cause of global mortality and morbidity . CLD patients are at an increased risk of developing liver fibrosis (formation of scar tissue), cirrhosis and liver failure and are at significant risk to develop primary liver cancer. Non-alcoholic fatty liver disease (NAFLD) represents a major risk for CLD and it is becoming the most common chronic liver condition with an estimated 25% global prevalence. Progression to non-alcoholic steatohepatitis (NASH) occurs in approx. 1 of 5 NAFLD patients and due to the rapidly rising etiology of end-stage liver disease, is currently the second most common etiology of hepatocellular carcinoma (HCC) requiring liver transplantation. Liver biopsy, currently the gold-standard for grading disease activity and staging fibrosis, is invasive, costly and at risk for sampling error. Due to the number of patients diagnosed with fibrosis and since fibrosis stage is prognostic of mortality and drives patient management, it is important to develop noninvasive yet accurate diagnostic tools that can identify fibrosis stage. The purpose of this study is to obtain a panel of clinically well characterized blood specimens to identify novel biomarkers to be used as an aid in diagnosis to assess the stage of clinically significant hepatic fibrosis in patients with signs or symptoms of NAFLD (NAFL\u002FNASH). In addition, quantitative ultrasound (QUS) based approaches combined with artificial intelligence (AI) algorithms will be explored for assessing the stage of fibrosis.",[26,69,71],"2026-05-22",{"date":112,"type":31},"2026-05-27",{"date":114,"type":31},"2025-02-01",{"date":116,"type":20},"2026-12",{"name":118,"class":119},"Roche Diagnostics GmbH","INDUSTRY",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":15,"minAge":127,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":21,"phases":131,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":39},"100571329","walking-program-in-fatty-liver-children-with-phenylketonuria-100571329","NCT06718842","Walking Program in Fatty Liver Children With Phenylketonuria","Walking Program in Fatty Liver Children With Phenylketonuria: Response of Liver Enzymes","Inclusion Criteria:\n\n* PKU children\n* obese children\n* fatty liver children (non-alcoholic fatty liver)\n\nExclusion Criteria:\n\n* cardiac children\n* diabetic children\n* neurogenic disorders\n* respiratory and renal problems","9 Years","12 Years",{"count":130,"type":20},40,[23],"phenylketonuria (commonly known as PKU) is an inherited disorder that increases the levels of a substance called phenylalanine in the blood. PKU is usually associated with many metabolic complication including non-alcoholic fatty liver",[134,70],"Phenylketonurias","2024-12-02",{"date":137,"type":31},"2024-12-05",{"date":139,"type":31},"2024-09-15",{"date":141,"type":20},"2025-01-30",{"name":143,"class":38},"Cairo University",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":21,"phases":153,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":39},"100555138","free-walking-exercise-in-obstructive-sleep-apnea-patients-with-non-alcoholic-fatty-liver-100555138","NCT06508190","Free Walking Exercise in Obstructive Sleep Apnea Patients With Non-alcoholic Fatty Liver","Impact of Free Walking Exercise on Obstructive Sleep Apnea Patients With Non-alcoholic Fatty Liver on Liver Enzymes, Degree of Exhaustion, and Quality of Sleep","Inclusion Criteria:\n\n* The body mass index (BMI) \\\u003C 35 kg\u002Fm2.\n* obstructive sleep apnea patients with fatty liver\n\nExclusion Criteria:\n\n* liver transplantation , alcoholic fatty liver, antipsychotic medications, bariatric surgery; cardiac , renal problem , liver cancer ; pregnancy,orthopedic problems, systemic diseases, respiratory dysfunctions, neurological dysfunctions.","65 Years",{"count":130,"type":20},[23],"Research evaluating the impact of continuous positive airway pressure (CPAP) \\& walking exercise on fatigue severity, liver enzymes and sleeping quality in patients with non-alcoholic fatty liver disease who also have obstructive sleep apnea. Forty patients are divided into two groups: twenty patients CPAP and other twenty patients for CPAP and walking program .",[156,26],"Obstructive Sleep Apnea","2024-07-13",{"date":159,"type":31},"2024-07-18",{"date":161,"type":31},"2024-07-12",{"date":163,"type":20},"2024-12-01",{"name":165,"class":38},"Ahram Canadian University",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":47,"enrollmentInfo":174,"targetDuration":176,"studyType":107,"phases":4,"briefSummary":177,"conditions":178,"keywords":179,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":194},"100377155","european-paediatric-non-alcoholic-fatty-liver-disease-registry-eu-pnafld-100377155","NCT04190849","European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD)","The European Paediatric Non-alcoholic Fatty Liver Disease Registry (EU-PNAFLD): a Prospective, Longitudinal Follow-up of Children With Non-alcoholic Fatty Liver Disease","EU-PNAFLD","Inclusion Criteria:\n\n* Diagnosis made under 18 years of age.\n* Diagnosis of NAFLD spectrum disease (simple steatosis (NAFL), steatosis with abnormal transaminases, NASH ± fibrosis or cirrhosis)\n* Diagnosis established by:\n\n  * Radiological evidence of hepatic steatosis (e.g. increased hepatic echogenicity on ultrasound), with\n  * Exclusion of secondary causes (negative serological liver screen for HBV\u002FHCV, caeruloplasmin \\>0.20g\u002FL, no history of excess alcohol consumption, no evidence of iron overload, and no clinically significant alpha-1 antitrypsin (A1AT) phenotype (i.e. SZ, ZZ, SS), with or without\n  * Histology (\\>5% steatosis and histology consistent with paediatric NAFLD)\n\nExclusion Criteria:\n\n* Secondary fatty liver disease (e.g. glycogen storage diseases, Wilson disease, viral hepatitis, drug-related, autoimmune hepatitis, type 1 diabetes mellitus)\n* Post-transplant fatty liver\n* \\>20g\u002Fday ethanol intake",{"count":175,"type":20},2000,"30 Years","The EU-PNAFLD (The European Paediatric NALFD Registry) will be a network composed of European centres involved in the care of children with NAFLD, and will include Hepatologists, Endocrinologists, and Scientists, supported by relevant international specialists. This collaboration will build on existing infrastructure (local databases and bio-repositories) and will align with the adult European NAFLD Registry (\"EPoS\", Elucidating Pathways of Steatohepatitis study) to allow long-term follow-up supported by translational studies. Through an international, well-characterised large-scale cohort, we hope to: facilitate multi-centre clinical trials; extend our understanding of the key disease mechanisms of NAFLD; and establish the natural history of paediatric NAFLD.",[69,26,71],[180,181,182,183,184],"Cirrhosis","Liver disease","Hepatocellular carcinoma","Type 2 diabetes","Atherosclerosis","2022-02-17",{"date":187,"type":31},"2022-03-04",{"date":189,"type":31},"2017-11-14",{"date":191,"type":20},"2047-11",{"name":193,"class":38},"Cambridge University Hospitals NHS Foundation Trust",3]